
Gender affirming hormonal treatment (GAHT) is a cornerstone in transgender care. National data are sparse regarding the use of hormonal treatment by transgender persons. This study aims to assess the use of GAHT in transgender persons. National register‐based cohort study on Danish transgender persons followed from 2000 until 2018. The main outcome measure was the prescription and purchase of GAHT. The cohort included 2789 transgender persons (n = 1717, CGI‐cohort and n = 1072, CPR‐cohort). In the CGI‐cohort, the event rate for GAHT in transgender women increased from 4.0 events per 100 people in the year 2000–2005 to 20.6 between 2014 and 2018. In transgender men, the event rate of GAHT increased from 4.2 to 18.8. The rate of discontinuation of GAHT was 0.06 per person year. The event rate of GAHT increased from 2000 to 2018. The data suggested high adherence to GAHT.
Like
Save
Share